Learn more about our Payment & Health Care Delivery Policy work.
AdvaMed, The Medtech Association®, released the following statement from President and CEO Scott Whitaker on the recently issued proposed Transitional Coverage for Emerging Technologies (TCET) rule.
This AdvaMed® position statement is intended to provide clarity about the transition away from the acronyms NDC/NHRIC to NRC, including rationale and implications.
This publication series explores “Software as a Medical Device (SaMD),” its challenges and the ways regulatory bodies try to address them, as well as the expected development of regulations related…
AdvaMed® launched a Strategic Value Initiative to develop principles and an approach for assessing the value of medical technologies that can be adopted by medtech companies, health systems, payers, and…
It is critical for diagnostic test developers to demonstrate the value of their tests to a variety of stakeholders. This framework serves as a resource for members to assess and…
From MDUFA V and the major investments in semiconductor chip manufacturing in the CHIPS Act, to addressing global supply chain issues and supporting our AdvaMed Accel® companies, 2022 was a…
Cary Vance, President and CEO of Titan Medical, joined AdvaMed®’s Scott Whitaker on the Medtech POV podcast to share his experience leading a small medical device company through the regulatory…
CEO and surgeon Dr. Lishan Aklog speaks about the tremendous value of medical technology, the sharp disparities patients face, and the importance of policymaking to ease those disparities.
AdvaMed® submitted comments to CMS on the CY 2023 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System proposed rule.
AdvaMed® submitted comments to CMS on the Calendar Year 2023 Physician Fee Schedule (PFS) proposed rule.